Drug Profile


Alternative Names: OPC-13013; OPC-21; Pletaal; Pletal

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Otsuka Pharmaceutical
  • Developer Otsuka Pharmaceutical; Pfizer
  • Class Antiplatelets; Quinolines; Small molecules; Tetrazoles
  • Mechanism of Action Platelet aggregation inhibitors; Type 3 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Arterial occlusive disorders; Intermittent claudication; Stroke
  • No development reported Angina pectoris
  • Discontinued Coronary artery restenosis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 21 Sep 2017 No development reported - Phase-III for Angina pectoris (In the elderly, Treatment-experienced, In adults) in South Korea (PO)
  • 01 Jan 2016 Otsuka Pharmaceuticals completes the phase III STELLA_Ext trial for Vasospastic Angina in South Korea (NCT02094469)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top